News on Active Biotech from BioPortfolio.com http://www.BioPortfolio.com Consolidated Active Biotech news from BioPortfolio.com Tue, 09 Feb 2010 16:22:15 GMT en Teva Acquires Marketing Rights for Oral Laquinimod in the Nordic and Baltic Regionshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4033171&HITNO=0&MSIZE=611&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Active%20Biotech&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4033171&THISHREF=http://c.moreover.com/click/here.pl%3fz2535047334%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4033171&HITNO=0&MSIZE=611&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Active%20Biotech&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4033171&THISHREF=http://c.moreover.com/click/here.pl%3fz2535047334%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comWeb Newswire: Teva Acquires Marketing Rights For Oral Laquinimod In The Nordic And Baltic Regionshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4033853&HITNO=1&MSIZE=611&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Active%20Biotech&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4033853&THISHREF=http://c.moreover.com/click/here.pl%3fz2535445039%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4033853&HITNO=1&MSIZE=611&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Active%20Biotech&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4033853&THISHREF=http://c.moreover.com/click/here.pl%3fz2535445039%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comPharmaceutical Online: Teva Acquires Marketing Rights for Oral Laquinimod in the Nordic and Baltic Regionshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4033015&HITNO=2&MSIZE=611&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Active%20Biotech&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4033015&THISHREF=http://c.moreover.com/click/here.pl%3fz2534953777%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4033015&HITNO=2&MSIZE=611&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Active%20Biotech&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4033015&THISHREF=http://c.moreover.com/click/here.pl%3fz2534953777%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comWebWire: Teva and Active Biotech amend marketing and distribution agreementhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4035113&HITNO=3&MSIZE=611&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Active%20Biotech&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4035113&THISHREF=http://c.moreover.com/click/here.pl%3fz2536119356%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4035113&HITNO=3&MSIZE=611&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Active%20Biotech&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4035113&THISHREF=http://c.moreover.com/click/here.pl%3fz2536119356%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comTradingMarkets: Teva Pharmaceutical Industries extends marketing rights for laquinimod, includes Nordic and Baltic regionshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4033189&HITNO=4&MSIZE=611&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Active%20Biotech&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4033189&THISHREF=http://c.moreover.com/click/here.pl%3fz2535053908%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4033189&HITNO=4&MSIZE=611&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Active%20Biotech&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4033189&THISHREF=http://c.moreover.com/click/here.pl%3fz2535053908%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comNews-Medical.Net: Teva and Active Biotech amend marketing and distribution agreementhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4035563&HITNO=5&MSIZE=611&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Active%20Biotech&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4035563&THISHREF=http://c.moreover.com/click/here.pl%3fz2536274944%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4035563&HITNO=5&MSIZE=611&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Active%20Biotech&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4035563&THISHREF=http://c.moreover.com/click/here.pl%3fz2536274944%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comIndividual.com: News and FDA Updates for Synta (NASDAQ:SNTA), Teva (NASDAQ:TEVA), Active Biotech (NASDAQ:ACTI)http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4035372&HITNO=6&MSIZE=611&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Active%20Biotech&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4035372&THISHREF=http://c.moreover.com/click/here.pl%3fz2536217649%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4035372&HITNO=6&MSIZE=611&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Active%20Biotech&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4035372&THISHREF=http://c.moreover.com/click/here.pl%3fz2536217649%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comLos Angeles Chronicle: News and FDA Updates for Synta (NASDAQ:SNTA), Teva (NASDAQ:TEVA), Active Biotech (NASDAQ:ACTI)http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4033945&HITNO=7&MSIZE=611&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Active%20Biotech&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4033945&THISHREF=http://c.moreover.com/click/here.pl%3fz2535503644%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4033945&HITNO=7&MSIZE=611&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Active%20Biotech&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4033945&THISHREF=http://c.moreover.com/click/here.pl%3fz2535503644%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comAmerican Chronicle: Teva acquires marketing rights for oral laquinimod in the nordic and baltic regionshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4034216&HITNO=8&MSIZE=611&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Active%20Biotech&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4034216&THISHREF=http://c.moreover.com/click/here.pl%3fz2535682140%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4034216&HITNO=8&MSIZE=611&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Active%20Biotech&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4034216&THISHREF=http://c.moreover.com/click/here.pl%3fz2535682140%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comMDLinx: Teva Acquires Marketing Rights For Oral Laquinimod In The Nordic And Baltic Regionshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4034215&HITNO=9&MSIZE=611&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Active%20Biotech&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4034215&THISHREF=http://c.moreover.com/click/here.pl%3fz2535682088%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4034215&HITNO=9&MSIZE=611&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Active%20Biotech&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4034215&THISHREF=http://c.moreover.com/click/here.pl%3fz2535682088%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comMDLinx: Teva and Active extend collaboration for multiple sclerosis drughttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4035543&HITNO=10&MSIZE=611&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Active%20Biotech&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4035543&THISHREF=http://c.moreover.com/click/here.pl%3fz2536271481%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4035543&HITNO=10&MSIZE=611&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Active%20Biotech&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4035543&THISHREF=http://c.moreover.com/click/here.pl%3fz2536271481%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comSmartBrief: SOA Software Expands European Operationhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4034405&HITNO=11&MSIZE=611&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Active%20Biotech&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4034405&THISHREF=http://c.moreover.com/click/here.pl%3fz2535771717%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4034405&HITNO=11&MSIZE=611&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Active%20Biotech&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4034405&THISHREF=http://c.moreover.com/click/here.pl%3fz2535771717%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comGenetic Engineering News: New European Device Clinical Requirements: Part 2http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4032891&HITNO=12&MSIZE=611&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Active%20Biotech&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4032891&THISHREF=http://c.moreover.com/click/here.pl%3fz2534851026%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4032891&HITNO=12&MSIZE=611&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Active%20Biotech&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4032891&THISHREF=http://c.moreover.com/click/here.pl%3fz2534851026%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comMedical Device Link: Teva Acquires Marketing Rights For Oral Laquinimod In The Nordic And Baltic Regionshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4031398&HITNO=13&MSIZE=611&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Active%20Biotech&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4031398&THISHREF=http://c.moreover.com/click/here.pl%3fz2534189301%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4031398&HITNO=13&MSIZE=611&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Active%20Biotech&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4031398&THISHREF=http://c.moreover.com/click/here.pl%3fz2534189301%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comPharmacy Choice: Teva Acquires Marketing Rights For Oral Laquinimod In The Nordic And Baltic Regionshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4029156&HITNO=14&MSIZE=611&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Active%20Biotech&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4029156&THISHREF=http://c.moreover.com/click/here.pl%3fz2533010455%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4029156&HITNO=14&MSIZE=611&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Active%20Biotech&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4029156&THISHREF=http://c.moreover.com/click/here.pl%3fz2533010455%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comPR inside: